The purpose of this study is to identify and validate a panel of genetic markers associated with selective serotonin reuptake inhibitors (SSRI)-induced behavioural activation in children and youth with major depressive disorder (MDD), anxiety disorders, or obsessive-compulsive disorder (OCD) that could be used clinically to reduce the incidence of this adverse event and improve health outcomes.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Pharmacogenomics variants associated with SSRI-induced behavioural activation
Timeframe: Baseline, study-enrollment
Assessment of behavioural activation
Timeframe: Baseline, at study enrollment
Abdullah A Maruf, BPharm, MPharm, PhD